目的 觀察參蓮膠囊聯(lián)合貝伐珠單抗注射液和FOLFOX方案（奧沙利鉑、亞葉酸鈣聯(lián)合5-氟尿嘧啶）治療晚期胃癌的臨床療效。方法 選取2019年3月—2020年11月鄭州頤和醫(yī)院收治的60例晚期胃癌患者，入選患者采用雙色球法分為對照組和治療組，每組各30例。對照組給予FOLFOX化療方案，第1天靜脈滴注注射用奧沙利鉑，85 mg/m²溶于0.9%氯化鈉溶液100 mL中。第1、2天靜脈滴注注射用亞葉酸鈣，200 mg/m²溶于0.9%氯化鈉溶液100 mL中，滴注完成后靜脈推注氟尿嘧啶注射液，400 mg/m²。第1天靜脈滴注貝伐珠單抗注射液，7.5 mg/kg溶于0.9%氯化鈉溶液100 mL中。治療組在對照組的基礎(chǔ)上口服參蓮膠囊，6粒/次，3次/d。兩組均以3周為1個周期，持續(xù)治療3個周期。觀察兩組療效，比較兩組生存質(zhì)量、血清腫瘤標志物水平。結(jié)果 治療后，治療組患者的客觀緩解率（ORR）、疾病控制率（CBR）均高于對照組（P<0.05）。治療后，治療組患者生存質(zhì)量提高率明顯高于對照組，生存質(zhì)量降低率低于對照組（P<0.05）。治療后，兩組血清糖鏈抗原199（CA199）、癌胚抗原（CEA）、胃癌抗原（CA724）水平降低（P<0.05），且治療組的血清CA199、CEA、CA724水平明顯低于對照組（P<0.05）。結(jié)論 參蓮膠囊聯(lián)合貝伐珠單抗注射液和FOLFOX方案治療晚期胃癌的療效顯著，可改善患者生存質(zhì)量，有效降低血清腫瘤標志物水平，安全性較好。

Objective To observe the clinical efficacy of Shenlian Capsules combined with Bevacizumab Injection and FOLFOX chemotherapy scheme (oxaliplatin, calcium folinate combined with fluorouracil) in treatment of advanced gastric cancer. Methods Patients (60 cases) with advanced gastric cancer in Zhengzhou Yihe Hospital from March 2019 to November 2020 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were given FOLFOX chemotherapy scheme:the first day, patients in the control group iv administered with Oxaliplatin for injection, 85 mg/m²added into 0.9% sodium chloride solution 100 mL; the first and second day, patients in the control group iv administered with Calcium Folinate for injection, 200 mg/m²added into 0.9% sodium chloride solution 100 mL, after the infusion, Fluorouracil for injection was injected intravenously, 400 mg/m². On the first day, patients in the control group iv administered with Bevacizumab Injection, 7.5 mg/kgadded into 0.9% sodium chloride solution 100 mL. Patients in the treatment group were po administered with Shenlian Capsules on the basis of the control group, 6 grains/time, three times daily. Three weeks was a treatment cycle, and patients in two groups were treated for 4 treatment cycles. After treatment, the clinical efficacies were evaluated, and the quality of life and the serum tumor markers in two groups were compared. Results After treatment, the objective remission rate (ORR) and disease control rate (CBR) in the treatment group were higher than those in the control group (P < 0.05). After treatment, the improvement rate of quality of life in the treatment group was significantly higher than that in the control group, and the reduction rate of quality of life in the treatment group was lower than that in the control group (P< 0.05). After treatment, the serum levels of CA199, CEA, and CA724 in two groups were significantly decreased (P < 0.05), and the serum levels of CA199, CEA, and CA724 in the treatment group were better than those in the control group (P < 0.05). Conclusion Shenlian Capsules combined with Bevacizumab Injection and FOLFOX chemotherapy scheme has clinical curative effect in treatment of advanced gastric cancer, can improve the quality of life of patients, and effectively reduce the serum level of tumor markers, with good safety.

R979.1

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（LHGJ20190394）